Comparative study of the unbinding process of some HTLV-1 protease inhibitors using Unbiased Molecular Dynamics simulation
Fereshteh Noroozi TiyoulaiD, Hassan AryapouriD, Mostafa Javaheri MoghadamiD
Abstract
The HTLV-1 protease is one of the major antiviral targets to overwhelm this virus. Several research groups have been developing protease inhibitors over the years, but none has been successful. In this regard, the development of new HTLV-1 protease inhibitors based on fixing the defects of previous inhibitors will overcome the absence of curative treatment for this oncovirus. Thus, we decided to study the unbinding pathways of the most potent (compound 10, Ki = 15 nM) and one of the weakest (compound 9, Ki = 7900 nM) protease inhibitors, which are very structurally similar, with the PDB IDs: 4YDG, 4YDF, using the Supervised Molecular Dynamics (SuMD) method. In this project, we had various short and long-time-scale simulations, that in total, we could have 12 successful unbindings (a total of 14.8 s) for the two compounds in both mp forms. This comparative study measured all the essential factors simultaneously in two different inhibitors, which improved our results. This study revealed that Asp32 or Asp32' in the two forms of mp state similarly exert super power effects on maintaining both potent and weak inhibitors in the binding pocket of HTLV-1 protease. In parallel with the important impact of these two residues, in the potent inhibitors unbinding process, His66' was a great supporter, that was absent in the weak inhibitors unbinding pathway. In contrast, in the weak inhibitors unbinding process, Trp98/Trp98' by pi-pi stacking interactions were unfavorable for the stability of the inhibitor in the binding site. In our opinion, these results will assist in designing more potent and effective inhibitors for the HTLV-1 protease.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 5
- FWCI
- 0.27
- Field percentile
- 48th percentile
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Comparative analysis of the unbinding pathways of antiviral drug Indinavir from HIV and HTLV1 proteases by Supervised Molecular Dynamics simulation
Farzin Sohraby, Hassan Aryapour·PLoS ONEPeer-reviewed·Sep 27, 2021
- Reconstruction of the binding pathway of an anti-HIV drug, Indinavir, in complex with the HTLV-1 protease by Unaggregated Unbiased Molecular Dynamics simulation
Farzin Sohraby, Hassan Aryapour·Computational Biology and ChemistryPeer-reviewed·Dec 3, 2021
- Structure-Based Pharmacophore Modeling, High-throughput Screening, and Molecular Dynamics Identify a Novel DrugBank-Derived HIV-1 Protease Inhibitor
Ali Sultan Khazaal Nazal, Amjed Majid Rashid Alrashedi, … Mustafa Abdulkadhim Hussein Ali Rabeea·PLoS ONEPeer-reviewed·Jun 12, 2026
- Pathway Specific Unbinding Free Energy Profiles of Ritonavir Dissociation From HIV-1 Protease
Emily Vig, Jianan Sun, Chia‐en A. Chang·BiochemistryPeer-reviewed·Feb 10, 2025
- Evolution of drug resistance drives progressive destabilizations in functionally conserved molecular dynamics of the flap region of the HIV-1 protease
Madhusudan Rajendran, Maureen C. Ferran, … Miranda L. Lynch·bioRxiv·Nov 22, 2022
- Inhibitor binding influences the protonation states of histidines in SARS-CoV-2 main protease
A. Pavlova, D. L. Lynch, … J. C. Gumbart·bioRxiv·Sep 7, 2020